Albumin-bound formulation of paclitaxel (Abraxane® ABI-007) in the treatment of breast cancer

Albumin-bound formulation of paclitaxel (Abraxane® ABI-007) in the treatment of breast cancer

Breast cancer is the most common type of malignancy diagnosed in women. In the metastatic setting this disease is still uncurable. Taxanes represent an important class of antitumor agents which have proven to be fundamental in the treatment of advanced and early-stage breast cancer, but the clinical...

Full description

Bibliographic Details
Main Authors: Miele, Evelina, Spinelli, Gian Paolo, Miele, Ermanno, Tomao, Federica, Tomao, Silverio
Format: Online
Language:English
Published: Dove Medical Press 2009
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2720743/
id pubmed-2720743
recordtype oai_dc
spelling pubmed-27207432009-08-31 Albumin-bound formulation of paclitaxel (Abraxane® ABI-007) in the treatment of breast cancer Miele, Evelina Spinelli, Gian Paolo Miele, Ermanno Tomao, Federica Tomao, Silverio Review Breast cancer is the most common type of malignancy diagnosed in women. In the metastatic setting this disease is still uncurable. Taxanes represent an important class of antitumor agents which have proven to be fundamental in the treatment of advanced and early-stage breast cancer, but the clinical advances of taxanes have been limited by their highly hydrophobic molecular status. To overcome this poor water solubility, lipid-based solvents have been used as a vehicle, and new systemic formulations have been developed, mostly for paclitaxel, which are Cremophor-free and increase the circulation time of the drug. ABI-007 is a novel, albumin-bound, 130-nm particle formulation of paclitaxel, free from any kind of solvent. It has been demonstrated to be superior to an equitoxic dose of standard paclitaxel with a significantly lower incidence of toxicities in a large, international, randomized phase III trial. The availability of new drugs, such as Abraxane®, in association with other traditional and non-traditional drugs (new antineoplastic agents and targeted molecules), will give the oncologist many different effective treatment options for patients in this setting. Dove Medical Press 2009 2009-04-20 /pmc/articles/PMC2720743/ /pubmed/19516888 Text en © 2009 Miele et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.
repository_type Open Access Journal
institution_category Foreign Institution
institution US National Center for Biotechnology Information
building NCBI PubMed
collection Online Access
language English
format Online
author Miele, Evelina
Spinelli, Gian Paolo
Miele, Ermanno
Tomao, Federica
Tomao, Silverio
spellingShingle Miele, Evelina
Spinelli, Gian Paolo
Miele, Ermanno
Tomao, Federica
Tomao, Silverio
Albumin-bound formulation of paclitaxel (Abraxane® ABI-007) in the treatment of breast cancer
author_facet Miele, Evelina
Spinelli, Gian Paolo
Miele, Ermanno
Tomao, Federica
Tomao, Silverio
author_sort Miele, Evelina
title Albumin-bound formulation of paclitaxel (Abraxane® ABI-007) in the treatment of breast cancer
title_short Albumin-bound formulation of paclitaxel (Abraxane® ABI-007) in the treatment of breast cancer
title_full Albumin-bound formulation of paclitaxel (Abraxane® ABI-007) in the treatment of breast cancer
title_fullStr Albumin-bound formulation of paclitaxel (Abraxane® ABI-007) in the treatment of breast cancer
title_full_unstemmed Albumin-bound formulation of paclitaxel (Abraxane® ABI-007) in the treatment of breast cancer
title_sort albumin-bound formulation of paclitaxel (abraxane® abi-007) in the treatment of breast cancer
description Breast cancer is the most common type of malignancy diagnosed in women. In the metastatic setting this disease is still uncurable. Taxanes represent an important class of antitumor agents which have proven to be fundamental in the treatment of advanced and early-stage breast cancer, but the clinical advances of taxanes have been limited by their highly hydrophobic molecular status. To overcome this poor water solubility, lipid-based solvents have been used as a vehicle, and new systemic formulations have been developed, mostly for paclitaxel, which are Cremophor-free and increase the circulation time of the drug. ABI-007 is a novel, albumin-bound, 130-nm particle formulation of paclitaxel, free from any kind of solvent. It has been demonstrated to be superior to an equitoxic dose of standard paclitaxel with a significantly lower incidence of toxicities in a large, international, randomized phase III trial. The availability of new drugs, such as Abraxane®, in association with other traditional and non-traditional drugs (new antineoplastic agents and targeted molecules), will give the oncologist many different effective treatment options for patients in this setting.
publisher Dove Medical Press
publishDate 2009
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2720743/
_version_ 1611440675445800960

Similar Items